Purpose: To determine whether Polo-like kinase 1 (PLK1) inhibitors (e.g., BI2536) and histone deacetylase (HDAC) inhibitors (e.g., vorinostat) interact synergistically in the BCR/ABL þ leukemia cells sensitive or resistant to imatinib mesylate (IM) in vitro and in vivo. Experimental Design: K562 and LAMA84 cells sensitive or resistant to imatinib mesylate and primary CML cells were exposed to BI2536 and vorinostat. Effects on cell viability and signaling pathways were determined using flow cytometry, Western blotting, and gene transfection. K562 and BV173/E255K animal models were used to test in vivo efficacy.
Introduction
Chronic myelogenous leukemia (CML) is neoplastic stem cell disorder characterized by the 9,22 translocation, producing the BCR/ABL fusion protein, a constitutively active kinase which signals downstream to multiple antiapoptotic proteins (e.g., CRKL, STAT5, and Bcl-xL; ref. 1) . CML treatment has been revolutionized by the BCR/ABL kinase inhibitor imatinib mesylate (IM) and second-generation agents (e.g., nilotinib, dasatinib, and bosutinib; refs. 2, 3) . Despite long-term responses to these agents, drug intolerance, the development of resistance-conferring mutations (e.g., T315I), and the failure to eradicate primitive leukemia-initiating cells represent therapeutic challenges (4) . In addition, patients in blast phase of CML or with Ph 1þ acute lymphoblastic leukemia (ALL) generally respond poorly to therapy (5) . Consequently, the need for new and more effective treatment options remains.
Polo-like kinase 1 (PLK1) is a conserved serine-threonine kinase involved in mitotic progression through interactions with cyclin B, the CDC25C phosphatase, and Wee1 (6) . It has been implicated in progression into M phase, mitotic spindle formation, cytokinesis, and chromosome segregation (7) . PLK1 modulates DNA damage responses, including recovery from the G 2 DNA damage checkpoint (8) . Moreover, interactions between PLK1 and multiple checkpoint proteins, including Chk1/2, p53, claspin, and FoxM1, have been described (9) . PLK1 is highly expressed in multiple malignancies, including leukemia (10) and lymphoma (11) , prompting the development of multiple PLK1 inhibitors, including the specific ATP-competitive inhibitor BI2536, which displays a 10,000-fold increase (12) in specificity for PLK1 compared with other tyrosine and threonine kinases (12) . It was recently reported that PLK1 represented a downstream target of BCR/ABL in CML cells and that PLK1 interruption by inhibitors such as BI2536 or short hairpin RNA (shRNA) knockdown promoted leukemia cell death in highly imatinib mesylate-resistant cells expressing BCR/ABL gatekeeper mutations (e.g., T315I; ref. 13 ). BI6727 (volasertib) is a highly potent, clinically relevant PLK1 inhibitor which has superior pharmacokinetic properties compared with BI2536 (14) .
Histone deacetylase inhibitors (HDACI) act by modifying chromatin structure and, by extension, gene expression (15) . These agents also trigger acetylation of various nonhistone proteins, particularly those implicated in DNA damage responses, including DNA repair proteins (Ku70) and chaperone proteins (Hsp90; ref. 16 ). In addition, HDACIs downregulate DNA repair proteins (e.g., Rad51 and MRE11; refs. 17). Indeed, HDACI lethality has been attributed to oxidative injury [e.g., reactive oxygen species (ROS); ref. 18 ], due to impaired induction of antioxidant proteins (19) . HDACIs have been shown to enhance the activity of tyrosine kinase inhibitors in CML cells (20) , including early progenitor cells (21 
Materials and Methods
Cells LAMA 84 cells were purchased from the German Collection of Microorganisms and Cell Cultures. K562 and BaF/3 cells were obtained as before (22) . Cells were cultured in RPMI media as described previously (22) . CD34 þ cells were obtained with informed consent from patient bone marrows and processed as before (22) . CML adult T315I and BV173/E255K ALL cells were generated as described (23) . K562 cells expressing ectopically PLK1-CA or shRNA/scrambled sequence were generated by electroporation (Amaxa) as described (24) . K562 and LAMA84 cell lines were authenticated by STR DNA fingerprinting using the AmpFlSTR Identifiler Kit (Applied Biosystems). The short tandem repeat (STR) profiles were compared with known American Type Culture Collection database and to the German Collection of Microorganisms and Cell Cultures database (http://www.dsmz.de/).
Reagents
PLK1 inhibitors BI2536 and BI6277 were purchased from ChemieTek Inc. and Selleck BioChem. GW843682 and 7-aminoactinomycin D (7-AAD) were from Sigma-Aldrich and vorinostat was from Merck. All drugs were formulated in sterile dimethyl sulfoxide (DMSO) before use. Annexin V/propidium iodide (PI) was from BD PharMingen and MnTBAP was from Calbiochem.
Assessment of cell viability and apoptosis
Cell viability was monitored by flow cytometry using 7-AAD as before (24) . Apoptosis was evaluated by Annexin V/ PI staining (24) and verified by Wright-Giemsa staining. Results of morphologic assessment, 7-AAD staining, and Annexin V/PI staining were highly concordant.
Separation of S-100 fractions and assessment of cytochrome c release Cells were harvested and cytosolic S-100 fractions were prepared as before (22, 24) . Western blot analysis assessing cytochrome c, SMAC, and AIF release was conducted as below.
Immunoblot analysis
Immunoblotting was conducted as described previously (22, 24) . Primary antibodies were as follows: AIF, cytochrome c, p-stat5, stat5, p-ATM, and ATR (Santa Cruz Biotechnology); p-BCR/ABL, BCR/ABL, p-PLK1(Thr210), PLK1, cleaved caspase-3, and p-ATR (Cell Signaling Technology); PARP (C-2-10; BioMol Research Laboratories); SMAC and gH2A.X (Upstate Biotechnology); tubulin (Oncogene); ATM and Histone1.2 (Abcam); and p-PLK1 (Ser137; Millipore).
Translational Relevance
The introduction of BCR/ABL kinase inhibitors, such as imatinib or dasatinib, resulted in improved treatment for patients with chronic myelogenous leukemia (CML) but many become refractory through various mechanisms, including mutations in kinase domain. Consequently, novel strategies are urgently needed to this disease. Recent evidence that Polo-like kinase 1 (PLK1) acts downstream of BCR/ABL makes it an attractive target for CML therapy, as it may be capable of circumventing resistance to BCR/ABL kinase inhibitors. The present findings indicate that histone deacetylase (HDAC) inhibitors, such as vorinostat, interact synergistically with a clinically relevant PLK1 inhibitor (BI2536) in imatinib mesylate-resistant cells both in vitro and in vivo through multiple mechanisms, raising the possibility that a combined HDAC/PLK1 inhibitor strategy may be of value in patients with CMLs resistant to standard approaches.
Measurement of ROS production
Cells were treated with 20 mmol/L 2 0 ,7 0 -dicholorodihydrofluorescein diacetate for 30 minutes at 37 C, and fluorescence was monitored by flow cytometry and analyzed with CellQuest software (25) .
Cell-cycle analysis
Cell-cycle distribution was determined by flow cytometry using a commercial software program (ModFit, Becton Dickinson) as per standard protocol (25) .
Plasmids and shRNA
Plasmids encoding Homo sapiens PLK1 in pCMV6-Entry vectors were obtained from Origene Technologies. Four separate sequences were used to knock down PLK1 (i.e., 1-GGCAAGATTGTGCCTAAGTCTCTGCTGCT, 2-ACCAGCA-CGTCGTAGGATTCCACGGCTT, 3-TCACAGTCCTCAATAA-AGGCTTGGAGAAC, 4-TGGACTGGCAACCAAAGTCGAA-TATGACG) and one nonspecific control sequence (NC-GGAATCTCATTCGATGCATAC) as negative control. Similarly, the following sequences are used to known down Histone 1.2 (AAGGTTGCGAAGCCCAAGAAA, NC-GGAAT-CTCATTCGATGCATAC from SA Biosciences). Details of the shRNA for knocking down HDAC1-3 are follows (sh-HDAC1: 5 0 -GCTCCATCCGTCCAGATAACA-3 0 ; shHDAC2: values were determined by comparing results obtained for untreated controls and treated cells following exposure to agents administered at a fixed ratio (BI: vor ¼ 1:300), after which median dose-effect analysis was used to characterize the nature of the interaction. Combination index (CI) values less than 1.0 denote a synergistic interaction. D, K562 cells were treated with BI2536 (5 nmol/L) AE vorinostat (1.5 mmol/L) for 48 hours, after which cells were washed and plated in soft agar as described (23) . Colonies, consisting of groups ! 50 cells, were scored at day 10. Values for each condition were expressed as a percentage of control colony formation. In all cases, values correspond to the means for triplicate determinations AE SD. A and B, Ã , significantly more than values for cells exposed to either BI2536 or vorinostat alone; P < 0.02; D, ÃÃ , significantly less than values for cells exposed to either BI2536 or vorinostat alone; P < 0.01. For all studies, values represent the means for 3 experiments carried out in triplicate AE SD.
Transient transfections
Transient transfections of K562 cells used an Amaxa Nucleofector. Protocols for each cell line used Transfection Kit V and a cell-specific optimized protocol (T-16) as before (22) .
Animal studies
Animal studies used Beige-nude-XID mice (NIH-III; Charles River). A total of 10 Â 10 6 K562 cells were pelleted, washed twice with 1 Â PBS, and injected subcutaneously into the right flank. Once tumors were visible, 5 to 6 mice were treated with BI2536 with or without vorinostat and tumor growth or regression monitored as before (24, 25) . To investigate effects of tumor size on regimen efficacy, experiments were carried out with different initial tumor sizes [e.g., (i) average, 150 mm 3 and (ii) average, 550 mm 3 . Systemic tumor models used BV173/E255K/Luc cl4 cells as described earlier (23) . Briefly, 2 Â 10 6 BV173/E255K/Luc cl4 cells in 100 mL PBS were tail vein injected and animals noninvasively imaged using an in vivo Imaging System (IVIS-200; Xenogen) following luciferase injection (D-luciferin; Research Products International). BI2536 was administered orally by gavage; vorinostat was given intraperitoneally. Both drugs were given simultaneously daily, 3 days a week (TIW). BI2536 was dissolved in 0.1 (N) HCl solution; 0.9% NaCl was added as diluent. The BI2536 volume was 100 mL. Vorinostat was administered as described (24) .
Statistical analysis
The significance of differences between experimental conditions was determined with the 2-tailed Student t test. Synergistic and antagonistic interactions were characterized using median dose-effect analysis in conjunction with a commercially available software program (CalcuSyn; ref. 26) .
Results
HDACIs dramatically increase PLK1 lethality toward IM-sensitive or -resistant BCR/ABL þ leukemia cells but
Concomitant exposure (48 hours) of K562 cells to vorinostat (1.5 mmol/L) and very low, minimally toxic (e.g., 3 nmol/L) concentrations of BI, significantly increased apoptosis, which exceeded 80% at 5 to 6 nmol/L BI2536 ( index values considerably below 1.0, reflecting a highly synergistic interaction (Fig. 1C) . Combined treatment also strikingly reduced colony formation of K562 cells (Fig. 1D) . In contrast, individual or combined treatment with BI and vorinostat minimally affected normal CD34 þ cells (Supplementary Fig. S1B ). Similar interactions were observed when BCR/ABL þ LAMA84 were exposed to BI (2.0 nmol/L) and 1.0 mmol/L vorinostat ( Supplementary Fig. S2A ) or in K562 cells exposed to other PLK1 inhibitors (e.g., BI6277 or GW843682) or HDACIs (e.g., vorinostat or SBHA; Supplementary Fig. S2B ).
Median dose-effect analysis revealed synergism between GW843682 and vorinostat in LAMA84 cells ( Supplementary  Fig. S2C) HDACI/BI2536 co-administration enhances BCR/ABL inhibition and DNA damage Effects of vorinostat/BI2536 on various signaling and survival events were examined. These studies were conducted at relatively early exposure intervals and before the onset of extensive apoptosis (e.g., 24 hours). Combined treatment of K562 cells with BI2536 (5 nmol/L) and vorinostat (1.5 mmol/L) resulted in a marked increase in cytochrome c, AIF, and SMAC release into the cytosolic fraction, accompanied by enhanced PARP and caspase-3 cleavage ( Fig. 2A and B) . While the agents administered alone had little effect on BCR/ABL phosphorylation, combined treatment induced modest reductions in phospho-BCR/ABL expression but not total expression (Fig. 2B) . Combined treatment had little effect on T210 phosphorylation of PLK1 but clearly reduced S137 phospho-PLK1. No changes in total PLK1 were noted. Finally, combined treatment reduced levels of phospho-STAT5, a downstream BCR/ABL target (27) .
While vorinostat alone modestly upregulated histone 1.2, a marker of DNA damage (28), co-administration of BI-2536, which had no effect by itself, dramatically increased histone 1. Fig. 2C ). Combined treatment also resulted in clear increases in phosphorylation of the checkpoint proteins ATR and ATM (Fig. 2C) , accompanied by downregulation of DNA repair proteins (e.g., MLH1, MSH3, MSH6, MRE11, and RAD51; Fig. 2D ). Increased DNA damage occurred in highly imatinib mesylate-resistant BV173/E255 ALL cells (Fig. 2E) . Finally, time course studies of K562 cells exposed to BI2536 and vorinostat resulted in clear increases in gH2A. X formation and ATM phosphorylation at 12 hours and ATR phosphorylation at 18 hours (Fig. 2F) . In separate studies, co-administration of the broad caspase inhibitor BOC-FMK did not prevent DNA damage or ATM/ATR phosphorylation by the BI2536/vorinostat regimen (data not shown). Finally, histone 1.2 knockdown significantly reduced BI2536/vorinostat lethality (P < 0.05; Supplementary Fig. S3A ) and diminished PARP cleavage (Supplementary Fig. S3B ). Collectively, these findings indicate that the BI2536/vorinostat regimen downregulates various survival proteins and promotes DNA damage in BCR/ ABL þ leukemia cells and argue for a functional role for DNA damage in lethality.
PLK1 depletion increases HDACI lethality in BCR/ABL þ cells
To evaluate the functional significance of PLK1 in these interactions, K562 cells ectopically expressing PLK1 were generated. Two clones (CA6 and CA9) expressing significantly greater levels of PLK1 than scrambled controls (Fig. 3A, inset) were used. The lethality of the BI2536 regimen in PLK1-expressing clones was significantly attenuated (P < 0.05) compared with controls (Fig.  3A) . Conversely, shRNA knockdown of PLK1 (Fig. 3B , inset) significantly increased vorinostat lethality (Fig. 3B) . Finally, PLK1-knockdown cells exposed to vorinostat exhibited significant increases in caspase-3 cleavage, gH2A.X formation, and ATM phosphorylation compared with controls (Fig. 3C) .
ROS generation by the BI2536/vorinostat regimen plays a significant functional role in lethality
Previous evidence implicated oxidative injury in HDACI lethality toward myeloid leukemia cells (18, 30) . While BI2536 and vorinostat alone modestly induced ROS, manifested as early as 30 minutes after administration and increasing over the ensuing 24 hours, combined treatment significantly increased ROS levels (Fig. 4A) . Notably, the ROS scavenger TBAP blocked ROS generation (Fig. 4B ) as well as lethality (Fig. 4C ) in BI2536/vorinostat-treated cells. TBAP also blocked BI2536/vorinostat-mediated caspase-3 and PARP cleavage, gH2A.X formation, and ATM/ATR phosphorylation (Fig. 4D) , suggesting a functional role for oxidative injury in DNA damage and lethality. Previous studies have implicated HDACs (e.g., HDAC3) in the DNA damage response (31) . Consequently, the effects of HDAC knockdown on responses to BI2536 were examined. Three transiently transfected lines exhibiting knockdown of HDAC1-3 respectively (Fig. 5A, inset) were significantly more susceptible to BI2536 lethality (2.5-7.5 nmol/L) than controls (Fig. 5A) . Moreover, HDAC3 knockdown cells exposed to BI2536 displayed increased caspase-3 and PARP cleavage, lH2A.X formation, and phospho-ATR compared with controls (Fig. 5B) . Similar results were obtained in HDAC1 or 2 knock-down cells (data not shown), arguing that interference with HDAC function contributes to BI2536/vorinostat anti-leukemic interactions.
Co-administration of BI2536 prevents vorinostatinduced G 1 arrest and promotes G 2 -M accumulation
Exposure to vorinostat alone (24 hours) induced a marked increase in the G 1 fraction, consistent with previous reports (refs. 32, 33; Supplementary Fig. S4A ). BI2536 by itself modestly increased G 2 -M accumulation and slightly reduced the G 1 fraction. However, vorinostat/ BI2536 co-administration induced pronounced G 2 -M accumulation, accompanied by an increase in the subdiploid (apoptotic) population (Supplementary Fig.  S4A ). Virtually identical changes were observed in PLK1 shRNA knockdown cells exposed to vorinostat but not in controls ( Supplementary Fig. S4B and S4C ), raising the possibility that abrogation of HDACI-mediated G 1 arrest and accumulation of cells in G 2 -M may be due to enhanced DNA damage may contribute to BI2536/vorinostat lethality.
The BI2536/vorinostat regimen displays striking in vivo activity in early-and late-stage BCR/ABL þ xenograft models To assess the in vivo activity of the BI2536 regimen, 2 xenograft models were used. In the first, Beige mice were injected in the flank with 10 Â 10 6 K562 cells; when tumors were first visible (volumes < 150 mm 3 ), animals were treated with BI2536 (30 mg/kg) AE vorinostat (70 mg/kg) for 2 weeks. Alternatively, identical treatment regimens were initiated when tumor volumes exceeded 550 mm 3 . In the first model, vorinostat alone had little effect whereas BI2536 delayed but did not prevent tumor growth (Fig. 6A) . However, combined treatment essentially abrogated tumors, which did not recur during the entire 38-day observation period. In the late-stage model, vorinostat alone had no effect, whereas BI2536 along marginally delayed tumor growth (Fig. 6B) . However, combined treatment substantially reduced tumor size over the entire observation period. Western blot analysis of tumor sections obtained after 6 days of treatment (early-stage model) revealed that combined but not single-agent treatment downregulated phospho-BCR/ABL and downstream targets (phospho-STAT5 and -CRKL) while increasing PARP/caspase-3 cleavage and gH2A.X formation (Fig. 6C) . Similar results were obtained in day-21 specimens (data not shown). Finally, BI2536 (30 mg/kg) and vorinostat (70 mg/kg) cotreatment significantly increased animal survival compared with no or single-agent treatment in a systemic imatinib-resistant luciferase-labeled BV173/E255K model (P < 0.05; Fig. 6D ). Tumor weights for all treatment groups did not decline by more than 10%, and no other signs of toxicity (torpor, weight loss, etc.) were observed (data not shown).
The marked reduction in size of the flank tumors in BI2536/vorinostat-treated animals is shown in at the end Fig. S5A ) and 14 days after terminating the treatment (Supplementary Fig. S5B ). Finally, combined treatment substantially reduced tumor growth compared with single-agent treatment in a systemic, luciferase-labeled BV173/E255K model system (Supplementary Fig. S5C ). Collectively, these findings indicate that combined in vivo treatment with BI2536 and vorinostat induces many of events observed in in vitro studies and that this regimen exhibits pronounced in vivo activity against early-and late-stage leukemia xenograft models.
Discussion
The present results indicate that HDACIs strikingly increase PLK1 inhibitor (e.g., BI2536) lethality in BCR/ ABL þ leukemia cells, including those exhibiting marked resistance to imatinib mesylate through gatekeeper or other mutations. Previously, BI2536 showed single-agent activity against such cells and suggested that PLK1 represents an important BCR/ABL downstream target responsible for survival functions (13) . Notably, HDACIs have been shown to enhance BCR/ABL kinase inhibitor activity through various mechanisms, including BCR/ABL downregulation due to chaperone function disruption (20, 34) or enhanced BCR/ABL inhibition (35) . Here, vorinostat/ BI2536 promoted modest inactivation/dephosphorylation of BCR/ABL and its downstream target STAT5 (27) . The mechanism underlying HDACI/BI2536-mediated disruption of the BCR/ABL pathway remains to be determined, as does the contribution of BCR/ABL inhibition to lethality. Indeed, preliminary studies in BCR/ ABL-negative acute myelogenous leukemia (AML) cells suggest similar PLK1/HDAC inhibitor interactions 3 and treated with the designated doses of BI2536 AE vorinostat thrice weekly as described in Materials and Methods for 14 or 24 days, respectively. Tumor volumes were measured twice weekly and mean tumor volumes were plotted against days of treatment. Tumor samples were extracted from mice after (C) 6 days (early-stage model) and of drug treatment and lysed with lysis buffer followed by sonication. Western blotting was conducted using the extracted proteins, which were probed with the indicated primary antibodies. Each lane was loaded with 20 mg of protein; blots were subsequently stripped and reprobed with antibodies to tubulin to ensure equivalent loading and transfer. D, survival curves of individual groups with systemically IM-resistant BV173/E255K tumors after 24 days following treatment with BI2536 (30 mg/kg) AE vorinostat (70 mg/kg) TIW. Control, blue; BI2536, green; vorinostat, yellow; BI2536 þ vorinostat, purple, Survival was evaluated from the first day of treatment until death using Kaplan-Meier analysis ( Ã , P < 0.05).
(Dasmahapatra and Grant, unpublished observations). Such findings argue that BCR/ABL pathway inhibition is unlikely to be the sole mechanism of lethality for this regimen. Finally, vorinostat potentiated BI2536-mediated inhibition of PLK1 phosphorylation at Ser137, which has been implicated in late mitotic progression and the mitotic spindle checkpoint (36) , potentially contributing to lethality. The present results suggest that enhanced HDAC/PLK1 inhibitor lethality involves potentiation of DNA damage. HDACIs induce DNA damage through diverse mechanisms, including downregulation of DNA repair proteins (e.g., RAD51 and MRE11; ref. 17) or acetylation (e.g., Ku70; ref. 37). PLK1 also plays an important role in the mitotic spindle apparatus and DNA damage responses (38) , suggesting that enhanced lethality stems from the disabling of the DNA damage and repair response. In support of this concept, combining BI2536 with vorinostat sharply increased expression of the atypical histone gH2A.X, reflecting double-strand DNA breaks (29) and DNA damage checkpoint kinase activation (ATM and ATR). Moreover, BI2536/vorinostat co-exposure produced reductions in the expression of multiple DNA repair proteins, including RAD51, MRE11, ERCC1, MSH2/6, and MLH1, compared with vorinostat alone. The mechanism underlying this phenomenon remains to be determined, but as in the case of BCR/ABL inactivation, may represent secondary, apoptosis-related events. In this context, knockdown of HDACIs (e.g., HDAC3) promotes DNA damage (31), possibly reflecting the contribution of HDACs to DNA repair complexes (39) . Consistent with these findings, HDAC1-3 knockdown significantly increased BI2536-mediated DNA damage and lethality. Conversely, ectopic PLK1 expression significantly reduced BI2536/vorinostatmediated apoptosis, whereas shRNA PLK1 knockdown significantly increased vorinostat-induced cell death, implicating on-target actions in synergistic interactions. Finally, the observation that knockdown of histone 1.2, which links DNA damage to the apoptotic apparatus (28) significantly protected cells, argues for a functional role for DNA damage in lethality.
HDACIs have been shown to kill transformed cells, including leukemia cells, through the induction of ROS (18) , and selective induction of oxidative injury in transformed cells may reflect impairment in upregulation of antioxidant proteins (e.g., thioredoxin reductase; ref. 40) . On the other hand, a link between PLK1 and oxidative injury has not previously been described. Interestingly, while minimally toxic vorinostat or BI2536 concentrations modestly induced ROS, combined treatment resulted in significant increases as early as 30 minutes after drug exposure which persisted over the ensuing 24 hours. The ability of the antioxidant TBAP to block BI 2536/vorinostat-mediated ROS generation and lethality indicates an important functional role for oxidative injury in synergistic interactions. While ROS generation could stem from DNA damage (41) , the observation that TBAP blocked gH2A.X formation and ATM/ATR activation suggests that ROS generation operates upstream of DNA breaks.
In cells sustaining DNA damage, HDACIs perturb the G 1 checkpoint (42, 43) , although interference with the intra-S (43) and G 2 -M checkpoints (43) has also been described. Here, minimally toxic concentrations of vorinostat induced marked G 0 -G 1 arrest, consistent with the ability of this agent to upregulate p21 CIP1 (32) . Exposure to BI2536 or PLK1 knockdown produced modest but discernible G 2 -M accumulation, reflecting the role of PLK1 in mitotic progression (44) . Notably, vorinostat combined with BI2536 or PLK1 knockdown essentially abrogated G 0 -G 1 arrest and resulted in a striking accumulation of cells in G 2 -M phase. Thus, combining HDAC with PLK1 inhibition may disable the G 1 checkpoint while simultaneously increasing DNA damage, promoting accumulation of cells in G 2 -M and subsequently apoptosis.
The combination of BI2536 and vorinostat showed marked inhibition of tumor growth of imatinib mesylate-sensitive or -resistant BCR/ABL þ leukemias in both flank and systemic in vivo models and significantly increased survival compared with single agents. Notably, multiple events observed in cells exposed to these agents in vitro (e.g., BCR/ABL and STAT5 dephosphorylation, gH2A.X formation, and PARP cleavage occurred in vivo, suggesting that similar mechanisms may be operative in the latter setting. The relative lack of toxicity of this regimen was consistent with the minimal in vitro effects observed in normal hematopoietic cells (CD34 þ ). Transformed cells exhibit impaired DNA damage checkpoints (45) and increased PLK1 expression in leukemia (10) may reflect a compensatory mechanism designed to circumvent otherwise lethal effects of DNA damage. Thus, leukemia cells may be particularly vulnerable to a strategy combining PLK1 inhibition with HDACIs, which promote DNA injury while disrupting checkpoint mechanisms (46) . Of note, the BI2536/vorinostat regimen displayed significant activity against large tumors in immunocompromised mice. Such tumors tend to be resistant to both conventional and targeted therapy as a consequence of impaired vasculature, a hypoxic environment, and a low growth fraction (47) . The ability of the BI 2536/ vorinostat regimen to induce substantial tumor regression in advanced disease argues that resistance resulting from these mechanisms may be circumvented, at least in part, by the current strategy. HDACIs such as vorinostat are approved for the treatment of cutaneous T-cell lymphoma (CTCL; ref. 48) . However, while a role for these agents in CML has not yet been established, recent studies suggest that HDACIs may interact with tyrosine kinase inhibitors to target CML stem cells (49) . In light of preclinical evidence of activity of PLK1 inhibitors in CML (13) 
